Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

NCT00750152
View directory record Official record
Conditions
Tinea Cruris, Jock Itch
Interventions
NAFT-500, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05704738
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
98
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Withdrawn No phase listed Observational

Evaluation of Vitamin D Levels in Psoriasis Patients

NCT01903317
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 21, 2026, 5:10 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Topical Cannabidiol Application and Skin Vascular Reactivity

NCT05456113
View directory record Official record
Conditions
Effect of Drug
Interventions
Cannabidiol
Biological
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Occipital Blocks for Acute Migraine

NCT03526874
View directory record Official record
Conditions
Chronic Migraine, Headache, Episodic Migraine
Interventions
Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin D Levels Following Topical Application of Vitamin D Ointment

NCT02676674
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Dose 1, Dose 2
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

NCT05028582
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Roflumilast Foam 0.3%, Vehicle Foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
36
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

NCT02965924
View directory record Official record
Conditions
Assess Phenylephrine on EVP and IOP
Interventions
Phenylephrine 2.5%
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 21, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
ATX01 10%, ATX01 15%, Placebo
Drug
Lead sponsor
AlgoTherapeutix
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Clermont, Florida • Miami, Florida • Port Charlotte, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Intra-anal Oxymetazoline in Healthy Adult Volunteers

NCT03529487
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Oxymetazoline
Drug
Lead sponsor
RDD Pharma Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

NCT05066997
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01), Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 85 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Not listed Not applicable Interventional

Clinical Trial Comparing Tissue Adhesive Vs. Absorbable Suture Vs. Non-Absorbable Suture

NCT00292513
View directory record Official record
Conditions
Cyst of Face, Neck or Shoulder, Pilomatrixoma of Face, Neck or Shoulder
Interventions
standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)
Device
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
0 Years to 18 Years
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2006 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Vapocoolant (Pain Ease) Use for Venipuncture

NCT01712776
View directory record Official record
Conditions
Pain
Interventions
Vapocoolant (Pain Ease), Nature's Tears Sterile Water
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional

Impact of Topical Pharyngeal Anesthetics on Discharge of the Patients When Used in Conjunction With Propofol Sedation in Routine EGD's

NCT02507440
View directory record Official record
Conditions
Topical Anesthesia
Interventions
Lidocaine, Placebo, Propofol
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Topical Agent for Treatment of Red Skin

NCT00279890
View directory record Official record
Conditions
Rosacea, Bilaterally Symmetric Red Skin on Cheeks
Interventions
Topical SR-01
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840
View directory record Official record
Conditions
Prehypertension, Hypertension, Stage I
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tustin, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

NCT04520217
View directory record Official record
Conditions
Photosensitivity, Microvesicle Particle
Interventions
4% Imipramine Cream, Base Cream
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

NCT01766440
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Calcitriol 3 mcg/g ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
San Diego, California • Indianapolis, Indiana • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

NCT02564042
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
San Diego, California • North Logan, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

NCT02580370
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 21, 2026, 5:10 AM EDT